- Cost-effectiveness of axicabtagene ciloleucel vs. tisagenlecleucel for the treatment of 3L+ relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results
- Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory mantle cell lymphoma: a CIBMTR subgroup analysis by prior treatment
- Axicabtagene ciloleucel vein-to-vein time in trial or real-world settings vs other CAR T-cell therapies for relapsed/ refractory large B-cell lymphoma: a systematic literature review and meta-analysis
- Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (r/r) follicular lymphoma
- Long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 by age, prior therapies, and subsequent transplant
- A phase 3, randomized controlled study of axicabtagene ciloleucel versus standard-of-care therapy in patients with relapsed or refractory follicular lymphoma